Recruitment and development of talent in overseas markets and high-potency pharmaceuticals
First written in FY2016. 6 of 11 entries say "Advanced", first in FY2023. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Against this backdrop, the Company implemented wage increases exceeding the prevailing level in Toyama Prefecture for 2 consecutive years. It also decided to introduce a defined contribution pension (DC) plan with employee investment choices as part of efforts to advance human capital management, with implementation scheduled for December 2026.」
As measures to secure and retain personnel, the Company implemented wage increases exceeding the prevailing level in Toyama Prefecture for 2 consecutive years and plans to launch a defined contribution pension plan with employee investment choices in December 2026. - FY2025AdvancedAnnual report
「In April 2025, the Company introduced the Elder Program and the Young Growship Plan as career path programs, supporting the career development and skills enhancement of employees in their first year with the Company, primarily through selected elders.」
In addition to restructuring its existing personnel management system and introducing internal recruitment and secondment programs, the Company introduced the Elder Program and Growship Plan for younger employees in April 2025. - FY2024ReframedAnnual report
「To improve operational efficiency and secure personnel, the Company is promoting the development of IT infrastructure that enables flexible working arrangements and the elimination of inefficient operations. It also intends to enhance its career path programs and develop the next generation of successors by actively appointing younger employees to important internal projects.」
The Company has expanded its existing focus on securing and developing personnel for overseas operations and highly potent pharmaceuticals into human capital investment covering flexible working arrangements, career development, the appointment of younger employees, and development of the next generation of successors. - FY2023AdvancedAnnual report
「Since June 2020, the Company has been rebuilding its personnel management system. The main revisions from the previous system include changes to the personnel framework, such as a review of grades; the establishment of evaluation criteria, including the introduction of competency evaluations; and clarification of promotion standards. Following consideration and adjustment based on interviews with internal departments, the details were finalized, and full-scale operation of the new personnel management system began in June 2023. Going forward, the Company intends to strengthen human resource development by providing training and education based on job requirements under this system.」
In addition to its policy of securing and developing personnel capable of supporting overseas operations and highly potent pharmaceuticals, the Company completed the restructuring of its personnel management system and began full-scale operation of the new system in June 2023. - FY2018RestatedAnnual report
「Going forward, it will be particularly essential to secure and develop personnel familiar with research and development activities and various regulatory submission activities related to overseas operations and highly potent pharmaceuticals. Including these areas, the Company intends to strengthen the organizational structure across the Group.」
The Company reiterates its policy of securing and developing personnel capable of supporting overseas operations, highly potent pharmaceuticals, research and development, and regulatory submission activities. - FY2017RestatedAnnual report
「Going forward, it will be particularly essential to secure and develop personnel familiar with research and development activities and various regulatory submission activities related to overseas operations and highly potent pharmaceuticals. Including these areas, the Company intends to strengthen the organizational structure across the Group.」
The Company reiterates its policy of securing and developing personnel capable of supporting overseas operations, highly potent pharmaceuticals, research and development, and regulatory submission activities. - FY2016First statedAnnual report
「It is essential to secure and develop personnel familiar with research and development activities and various regulatory submission activities related to overseas operations and highly potent pharmaceuticals. Including these areas, the Company intends to strengthen the organizational structure across the Group.」
The Company is focusing on securing personnel capable of supporting overseas operations, highly potent pharmaceuticals, research and development, and regulatory submission activities.